Avalanche Biotechnologies, Inc., announced that it has entered into a “definitive agreement” to acquire the French company Annapurna Therapeutics SAS. The…
Articles by Margarida Azevedo, MSc
Chondrial Therapeutics recently announced that further development of its lead drug candidate for the treatment of Friedreich’s ataxia, TAT-Frataxin (TAT-FXN), will…
Catabasis Pharmaceuticals, Inc., recently announced that it will receive the Kyle Bryant Translational Research Award, given by the Friedreich’s Ataxia Research…
Annapurna Therapeutics has just announced it will collaborate with Weill Cornell Medicine to develop a market-leading partnership specialized in gene…
Retrotope recently announced a second clinical trial site, the Collaborative Neuroscience Network, LLC (CNS), has opened in Long Beach, California, as part of…
A team of researchers have identified six new, highly specific compounds that hold promise of bringing “new perspectives” to the…
A symposium focused on the rare genetic disease Friedreich’s ataxia, titled, “Understanding Energy for A Cure“, will gather some of the most…
The Muscular Dystrophy Association (MDA), together with the Friedreich’s Ataxia Research Alliance (FARA), have announced a new strategic partnership geared towards…
The Muscular Dystrophy Association, the world’s leading nonprofit health agency dedicated to save and improve the lives of people with muscle…
The National Ataxia Foundation, an organization dedicated to improving the lives of those affected by ataxia through support, education and research,…